Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Handb Exp Pharmacol ; 2022 Jun 30.
Article in English | MEDLINE | ID: mdl-35768555

ABSTRACT

The CLC family encompasses two functional categories of transmembrane proteins: chloride conducting channels and proton-chloride antiporters. All members in this chloride channel/transporter family consist of two identical protein subunits, and each subunit forms an independent ion-transport pathway, a structural architecture known as "double barrel." These CLC proteins serve biological functions ranging from membrane excitability and cell volume regulation to acidification of endosomes. Despite their ubiquitous expression, physiological significance, and resolved molecular structures of some of the family members, the mechanisms governing these molecules' biophysical functions are still not completely settled. However, a series of functional and structural studies have brought insights into interesting questions related to these proteins. This chapter explores the functional peculiarities underlying CLC channels aided by information observed from the chloride-proton antiporters in the CLC family. The overall structural features of these CLC proteins will be presented, and the biophysical functions will be addressed. Finally, the mechanism of pharmacological agents that interact with CLC channels will also be discussed.

2.
PLoS One ; 15(12): e0240704, 2020.
Article in English | MEDLINE | ID: mdl-33362212

ABSTRACT

CLC-0, a prototype Cl- channel in the CLC family, employs two gating mechanisms that control its ion-permeation pore: fast gating and slow gating. The negatively-charged sidechain of a pore glutamate residue, E166, is known to be the fast gate, and the swinging of this sidechain opens or closes the pore of CLC-0 on the millisecond time scale. The other gating mechanism, slow gating, operates with much slower kinetics in the range of seconds to tens or even hundreds of seconds, and it is thought to involve still-unknown conformational rearrangements. Here, we find that low intracellular pH (pHi) facilitates the closure of the CLC-0's slow gate, thus generating current inhibition. The rate of low pHi-induced current inhibition increases with intracellular H+ concentration ([H+]i)-the time constants of current inhibition by low pHi = 4.5, 5.5 and 6 are roughly 0.1, 1 and 10 sec, respectively, at room temperature. In comparison, the time constant of the slow gate closure at pHi = 7.4 at room temperature is hundreds of seconds. The inhibition by low pHi is significantly less prominent in mutants favoring the slow-gate open state (such as C212S and Y512A), further supporting the fact that intracellular H+ enhances the slow-gate closure in CLC-0. A fast inhibition by low pHi causes an apparent inverted voltage-dependent activation in the wild-type CLC-0, a behavior similar to those in some channel mutants such as V490W in which only membrane hyperpolarization can open the channel. Interestingly, when V490W mutation is constructed in the background of C212S or Y512A mutation, the inverted voltage-dependent activation disappears. We propose that the slow kinetics of CLC-0's slow-gate closure may be due to low [H+]i rather than due to the proposed large conformational change of the channel protein. Our results also suggest that the inverted voltage-dependent opening observed in some mutant channels may result from fast closure of the slow gate by the mutations.


Subject(s)
Chloride Channels/metabolism , Chlorides/metabolism , Ion Channel Gating , Protons , Chloride Channels/genetics , Glutamic Acid/genetics , HEK293 Cells , Humans , Hydrogen-Ion Concentration , Kinetics , Membrane Potentials , Mutagenesis, Site-Directed , Mutation , Patch-Clamp Techniques , Structural Homology, Protein
3.
Mol Immunol ; 59(1): 79-90, 2014 May.
Article in English | MEDLINE | ID: mdl-24491490

ABSTRACT

We have designed a 39 amino acid peptide mimic of the conformation-dependent main immunogenic region (MIR) of the Torpedo acetylcholine receptor (TAChR) that joins three discontinuous segments of the Torpedo α-subunit, α(1-12), α(65-79), and α(110 - 115) with two GS linkers: This 39MIR-mimic was expressed in E. coli as a fusion protein with an intein-chitin-binding domain (IChBD) to permit affinity collection on chitin beads. Six MIR-directed monoclonal antibodies (mAbs) bind to this complex and five agonist/antagonist site directed mAbs do not. The complex of MIR-directed mAb-132A with 39MIR has a Kd of (2.11±0.11)×10(-10)M, which is smaller than (7.13±1.20)×10(-10)M for the complex of mAb-132A with α(1-161) and about the same as 3.4×10(-10)M for that of mAb-132A with TAChR. Additionally, the 39MIR-IChBD adsorbs all MIR-directed antibodies (Abs) from an experimental autoimmune myasthenia gravis (EAMG) rat serum. Hence, the 39MIR-mimic has the potential to inactivate or remove pathogenic Torpedo MIR-directed Abs from EAMG sera and to direct a magic bullet to the memory B-cells that produce those pathogenic Abs. The hope is to use this as a guide to produce a mimic of the human MIR on the way to an antigen specific therapeutic agent to treat MG.


Subject(s)
Fish Proteins/immunology , Peptides/immunology , Receptors, Cholinergic/immunology , Torpedo/immunology , Amino Acid Sequence , Animals , Antibodies, Monoclonal/immunology , Antibody Affinity/immunology , Base Sequence , Binding Sites/genetics , Binding Sites/immunology , Blotting, Western , Drug Design , Fish Proteins/chemistry , Fish Proteins/genetics , Immune Sera/immunology , Models, Molecular , Molecular Mimicry , Molecular Sequence Data , Myasthenia Gravis/blood , Myasthenia Gravis/immunology , Peptides/chemistry , Peptides/genetics , Protein Binding/immunology , Protein Structure, Tertiary , Rats , Receptors, Cholinergic/chemistry , Receptors, Cholinergic/genetics , Torpedo/genetics
4.
Mol Immunol ; 58(1): 116-31, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24333757

ABSTRACT

To develop antigen-specific immunotherapies for autoimmune diseases, knowledge of the molecular structure of targeted immunological hotspots will guide the production of reagents to inhibit and halt production of antigen specific attack agents. To this end we have identified three noncontiguous segments of the Torpedo nicotinic acetylcholine receptor (AChR) α-subunit that contribute to the conformationally sensitive immunological hotspot on the AChR termed the main immunogenic region (MIR): α(1-12), α(65-79), and α(110-115). This region is the target of greater than 50% of the anti-AChR Abs in serum from patients with myasthenia gravis (MG) and animals with experimental autoimmune myasthenia gravis (EAMG). Many monoclonal antibodies (mAbs) raised in one species against an electric organ AChR cross react with the neuromuscular AChR MIR in several species. Probing the Torpedo AChR α-subunit with mAb 132A, a disease inducing anti-MIR mAb raised against the Torpedo AChR, we have determined that two of the three MIR segments, α(1-12) and α(65-79), form a complex providing the signature components recognized by mAb 132A. These two segments straddle a third, α(110-115), that seems not to contribute specific side chains for 132A recognition, but is necessary for optimum antibody binding. This third segment appears to form a foundation upon which the three-dimensional 132A epitope is anchored.


Subject(s)
Myasthenia Gravis/immunology , Receptors, Nicotinic/chemistry , Amino Acid Sequence , Animals , Antibodies, Monoclonal/immunology , Binding Sites, Antibody/immunology , Green Fluorescent Proteins/genetics , Humans , Molecular Sequence Data , Myasthenia Gravis/blood , Peptide Fragments/immunology , Protein Binding/immunology , Protein Conformation , Protein Structure, Tertiary , Receptors, Nicotinic/immunology , Recombinant Fusion Proteins/genetics , Sequence Analysis, Protein , Torpedo
5.
Biophys J ; 96(7): 2637-47, 2009 Apr 08.
Article in English | MEDLINE | ID: mdl-19348747

ABSTRACT

Using small-angle x-ray diffraction from centrifugally oriented acetylcholine receptor (AChR) enriched membranes coupled with anomalous scattering from terbium ions (Tb3+) titrated into presumed Ca2+ binding sites, we have mapped the distribution of Tb3+ perpendicular to the membrane plane using a heavy atom refinement algorithm. We have compared the distribution of Tb3+ in the closed resting state with that in the carbamylcholine-desensitized state. In the closed resting state we find 45 Tb3+ ions distributed in 10 narrow peaks perpendicular to the membrane plane. Applying the same refinement procedure to the data from carbamylcholine desensitized AChR we find 18 fewer Tb3+ ions in eight peaks, and slight rearrangements of Tb3+ density in the peaks near the ends of the AChR ion channel pore. These agonist dependent changes in the Tb3+ stoichiometry and distribution suggest a likely role for multivalent cations in stabilizing the different functional states of the AChR, and the changes in the Tb3+ distribution at the two ends of the pore suggest a potential role for multivalent cations in the gating of the ion channel.


Subject(s)
Carbachol/pharmacology , Cell Membrane/metabolism , Cholinergic Agonists/pharmacology , Receptors, Cholinergic/metabolism , Terbium/metabolism , Animals , Cell Membrane/drug effects , Ion Channel Gating/drug effects , Ion Channels/chemistry , Ion Channels/metabolism , Phase Transition , Porosity , Protein Stability , Protein Structure, Tertiary , Receptors, Cholinergic/chemistry , Scattering, Small Angle , Terbium/pharmacology , Titrimetry , Torpedo , X-Ray Diffraction
7.
Ann N Y Acad Sci ; 998: 101-13, 2003 Sep.
Article in English | MEDLINE | ID: mdl-14592867

ABSTRACT

Anti-acetylcholine receptor (AChR) monoclonal antibody 383C binds to the beta-hairpin loop alpha(187-199) of only one of the two Torpedo AChR alpha subunits. The loop recognized is associated with the alpha subunit corresponding to the high-affinity d-tubocurarine (dTC) binding site. Desensitization of the receptor with carbamylcholine completely blocks the binding of 383C. Mild reduction of AChR alpha subunit cys 192-193 disulfide with DTT and subsequent reaction with 5-iodoacetamidofluorescein label only the high-affinity dTC alpha subunit. Rhodamine-labeled alpha-bungarotoxin (R-Btx) binds to the unlabeled AChR alpha subunit as monitored by fluorescence resonance energy transfer between the fluorescein and rhodamine dyes. A 10-A contraction of the distance between the dyes is observed following the addition of carbamylcholine. In a small angle X-ray diffraction experiment exploiting anomalous X-ray scattering from Tb(III) ions titrated into AChR Ca(II) binding sites, we find evidence for a change in the Tb(III) ion distribution in the region of the ion channel following addition of carbamylcholine to the AChR. The carbamylcholine-induced loss of the 383C epitope, the 10-A contraction of the beta-hairpin loop, and the loss of multivalent cations from the channel likely represent the first molecular transitions leading to AChR channel opening.


Subject(s)
Cholinergic Agonists/chemistry , Receptors, Cholinergic/chemistry , Animals , Binding Sites , Carbachol/chemistry , Enzyme-Linked Immunosorbent Assay/methods , Fluorescence Resonance Energy Transfer/instrumentation , Fluorescence Resonance Energy Transfer/methods , In Vitro Techniques , Protein Folding , Protein Structure, Quaternary , Protein Subunits/metabolism , Receptors, Cholinergic/immunology , X-Ray Diffraction/instrumentation , X-Ray Diffraction/methods
8.
Ann N Y Acad Sci ; 998: 453-6, 2003 Sep.
Article in English | MEDLINE | ID: mdl-14592914

ABSTRACT

We propose a new classification for immune myasthenia based on antibody pattern. The types of immune myasthenia presently characterized by known antibody targets segregate into three groups: type 1, in which the muscle target is the acetylcholine receptor only; type 2, in which titin antibodies are present in addition to acetylcholine receptor antibodies; and type 3, in which muscle-specific kinase antibodies are present in the absence of acetylcholine receptor antibodies. The immune target is unknown in the patients with immune myasthenia not associated with these antibodies. This classification has advantages over the present classifications as regards homogeneity of groups, etiology, mechanism of disease, and prognosis.


Subject(s)
Antibodies/classification , Myasthenia Gravis/classification , Receptor Protein-Tyrosine Kinases/immunology , Receptors, Cholinergic/immunology , Antibodies/immunology , Antigen-Antibody Reactions , Connectin , Epitopes/immunology , Humans , Immunization , Muscle Proteins/immunology , Myasthenia Gravis/immunology , Protein Kinases/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...